Abstract B072: Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity

Abstract Immune checkpoint inhibitors targeting the negative regulators of T cell activation, PD-1 and CTLA-4, have transformed cancer therapy. Both targets are genetically associated with autoimmune disorders. Moreover, certain immune-related adverse events and autoimmune risk variants are linked to clinical efficacy of checkpoint inhibition. These associations suggest common principles governing successful cancer immunotherapy and autoimmune susceptibility. Here we show that ablation of the cytosolic DNA exonuclease TREX1, similar to genetic loss of clinically validated T cell checkpoints, predisposes mice to autoimmunity while promoting robust antitumor immunity. Constitutive TREX1 loss leads to early onset autoimmunity, characterized by multi-organ CD8+ T cell infiltration, myocarditis and Sjögren’s syndrome-like disease. In contrast, induced systemic TREX1 ablation in adult mice is well tolerated and promotes effective CD8+ T cell-driven antitumor immunity. Detailed phenotypic studies revealed a striking overlap between productive antitumor and pathogenic autoimmune CD8+ T cell responses. Collectively, we provide mechanistic evidence for interrelated mechanisms underlying autoimmunity and successful cancer immunotherapy, uncover key parallels between adaptive T cell and innate immune checkpoints, and suggest that targeting autoimmune risk genes including TREX1 represents a promising future avenue for cancer immunotherapy. Citation Format: Lim, Junghyun, Williams, Katherine, Mittman, Stephanie, Rodriguez, Ryan, Ogasawara, Annie, Pacheco Sanchez, Patricia, Barnett, Grace, Cruz Tleugabulova, Mayra, Nabet, Barzin, Hung, Jeffrey, Marroquin, Kevin, Lau, Shari, Lee, Serena, Tyler, Paul, Carbone, Elizabeth, Hough, Bridget, Corpuz, Janice, Murota, Haruka, Dere, Edward, Shiffman, Smadar, Schutt, Leah, Gill, Herman, Lau, Julia, De Simone, Marco, Tam, Lucinda, Rosse-Girma, Merone, Warming, Soren, Oh, Soyoung, Rutz, Sascha, He, Meng Xiao, Muller, Soren, West, Nathaniel, Brewer, Thomas, Desai, Prashant, Williams, Simon, Ziai, James, Qu, Yan, Klaus Heger. Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B072.

Authors

Publication Details

Journal
Cancer Immunology Research
Published
2026-02-18
DOI
https://doi.org/10.1158/2326-6074.io2026-b072
Primary Topic
interferon and immune responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract B072: Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity

Klaus Heger, Hough, Marroquin, Barnett et al.
Cancer Immunology Research
interferon and immune responses
article

Abstract B072: Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity

Klaus Heger, Hough, Marroquin, Barnett, Prashant, Haruka, Annie, Ziai, Murota, Lucinda, Smadar, Merone, Elizabeth, Qu, Patricia, He, Marco, Paul, Ryan, Williams, Stephanie, Thomas, Warming, Bridget, Grace, Muller, Shari, Nabet, Soyoung, Junghyun, Cruz Tleugabulova, Carbone, Hung, Soren, James, Meng Xiao, Rosse-Girma, Lau, Yan, Oh, West, Tyler, Corpuz, Katherine, Pacheco Sanchez, Ogasawara, Nathaniel, Lim, Lee, Edward, Schutt, Shiffman, Desai, Rodriguez, Mayra, Julia, Janice, Gill, Serena, Herman, Simon, Barzin, De Simone, Sascha, Tam, Jeffrey, Mittman, Kevin, Dere, Brewer, Leah, Rutz
article en

Abstract

Abstract Immune checkpoint inhibitors targeting the negative regulators of T cell activation, PD-1 and CTLA-4, have transformed cancer therapy. Both targets are genetically associated with autoimmune disorders. Moreover, certain immune-related adverse events and autoimmune risk variants are linked to clinical efficacy of checkpoint inhibition. These associations suggest common principles governing successful cancer immunotherapy and autoimmune susceptibility. Here we show that ablation of the cytosolic DNA exonuclease TREX1, similar to genetic loss of clinically validated T cell checkpoints, predisposes mice to autoimmunity while promoting robust antitumor immunity. Constitutive TREX1 loss leads to early onset autoimmunity, characterized by multi-organ CD8+ T cell infiltration, myocarditis and Sjögren’s syndrome-like disease. In contrast, induced systemic TREX1 ablation in adult mice is well tolerated and promotes effective CD8+ T cell-driven antitumor immunity. Detailed phenotypic studies revealed a striking overlap between productive antitumor and pathogenic autoimmune CD8+ T cell responses. Collectively, we provide mechanistic evidence for interrelated mechanisms underlying autoimmunity and successful cancer immunotherapy, uncover key parallels between adaptive T cell and innate immune checkpoints, and suggest that targeting autoimmune risk genes including TREX1 represents a promising future avenue for cancer immunotherapy. Citation Format: Lim, Junghyun, Williams, Katherine, Mittman, Stephanie, Rodriguez, Ryan, Ogasawara, Annie, Pacheco Sanchez, Patricia, Barnett, Grace, Cruz Tleugabulova, Mayra, Nabet, Barzin, Hung, Jeffrey, Marroquin, Kevin, Lau, Shari, Lee, Serena, Tyler, Paul, Carbone, Elizabeth, Hough, Bridget, Corpuz, Janice, Murota, Haruka, Dere, Edward, Shiffman, Smadar, Schutt, Leah, Gill, Herman, Lau, Julia, De Simone, Marco, Tam, Lucinda, Rosse-Girma, Merone, Warming, Soren, Oh, Soyoung, Rutz, Sascha, He, Meng Xiao, Muller, Soren, West, Nathaniel, Brewer, Thomas, Desai, Prashant, Williams, Simon, Ziai, James, Qu, Yan, Klaus Heger. Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B072.

Cancer Immunology ResearchVol. 14(2_Supplement)
Openalex Percentile: Top 50%
interferon and immune responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.